Response to the influenza vaccine based on estradiol use in menopausal women.
To assess the impact of 17β-estradiol in modulating the response to the influenza vaccine in postmenopausal women. A prospective cohort study was conducted with 46 healthy postmenopausal women aged 41-62 years without previous vaccination against the influenza virus. Evaluation of serum antibodies using hemagglutination inhibition and single radial hemolysis was performed at the Virology Laboratory of the Butantan Institute, São Paulo, Brazil, using serum samples collected at two time points: immediately before and one month after vaccination. In non-estradiol users (n=25), the median number of hemagglutination-inhibiting units (Log2) increased from 5.32 to 6.82 (p=0.003). In estradiol users (n=21), the median number of hemagglutination-inhibiting units (Log2) increased from 5.32 to 5.82 (p=0.149). The median hemolytic areas produced with the single radial hemolysis assay before and after the vaccine were 11 mm in both groups. In postmenopausal women, estrogen therapy did not have a positive influence on the production of antibodies against the influenza virus after vaccination, at least based on the formulation, time period, and methods used for quantifying these antibodies in the present study.